Nick Glassa, Minoru Takasatob, Pei Xuan Erb, Melissa Littleb, Drew Titmarsha,c, James Hudsond, Alejandro Hidalgoa, Dmitry Ovchinnikova, Enzo Porrellod, Ernst Wolvtanga, Justin J. Cooper-Whitea,e,f,*


aAustralian Institute for Bioengineering & Nanotechnology, The University of Queensland, St. Lucia, QLD.
Murdoch Children’s Research Institute, Melbourne, VIC.
c Glycotherapeutics Group, Institute of Medical Biology, Agency for Science, Technology and Research, Singapore 138648.
d School of Biomedical Sciences, The University of Queensland, St. Lucia, QLD.
e School of Chemical Engineering, The University of Queensland, St. Lucia, QLD.
f Biomedical Manufacturing, Manufacturing Flagship, CSIRO, Clayton, VIC..
* ;


The successful deployment of human stem cells (pluripotent (hPSCs) or mesenchymal (hMSCs)) in regenerative medicine applications depends on effective control of both their undifferentiated expansion and differentiation into desired lineages. We have developed scalable, valveless, continuous-flow microdevice platforms to probe the impacts of a range of microenvironmental parameters on stem cell behaviors so as to effect greater control over stem cell fate. For example, among these device platforms, our microbioreactor arrays (MBAs) have been designed to both provide a combinatorial set of defined factor compositions, and allow controlled accumulation of paracrine factors through the creation of perfused cellular microenvironments in parallel. Through screens of pluripotency maintenance and differentiation of hPSCs into primitive streak, cardiac and kidney cells, we have demonstrated the unique ability of this platform to separate, visualise, identify and modulate paracrine effects that are not otherwise readily accessible with standard culture formats. Culture conditions optimized with the arrays are readily translated to conventional static culture protocols. Most recently we have assessed the impacts and interplay of developmental factors on proliferation of hPSC-derived cardiomyocytes, exemplifying the potential utility of the device for patient-specific early drug stratification. These multiplexed microfluidic platforms can decipher factor interplay and signaling hierarchies that control stem cell fate, and are applicable as microenvironmental screening platforms for developmental biology, bioprocess optimisation, media formulation design, quality control for cellular therapies and cell-based drug screening.


Biographic Details

Nick Glass

Research Officer

The Australian Institute for Bioengineering and Nanotechnology, Australia


Research interests: microfabrication, microfluidics, nanotechnology, highthroughput screening, stem cells, regenerative medicine, 3D printing